A detailed history of Engineers Gate Manager LP transactions in Bio Atla, Inc. stock. As of the latest transaction made, Engineers Gate Manager LP holds 12,820 shares of BCAB stock, worth $3,589. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,820
Holding current value
$3,589
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$0.59 - $2.37 $7,563 - $30,383
12,820 New
12,820 $7,000
Q4 2023

Feb 14, 2024

BUY
$1.27 - $3.18 $25,439 - $63,698
20,031 New
20,031 $49,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $10.2M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.